Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
48%
Prostate Specific Antigen
46%
Castration Resistant Prostate Cancer
38%
Androgen Receptor
21%
Prodrug
20%
Thapsigargin
19%
Malignant Neoplasm
17%
Neoplasm
15%
Enzalutamide
14%
Abiraterone
9%
Prostate Specific Membrane Antigen
9%
Placebo
8%
Progression Free Survival
8%
Calcium Ion
7%
Disease
7%
Docetaxel
7%
Pharmacokinetics
7%
Proteinase
6%
Phase II Trials
5%
Overall Survival
5%
Topsalysin
5%
Serine Proteinase
5%
Mouse
5%
Programmed Cell Death
5%
Keyphrases
Prostate Cancer
52%
Prostate-specific Antigen
31%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
26%
Bipolar Androgen Therapy
21%
Enzalutamide
15%
Castration-resistant Prostate Cancer
12%
Androgen Receptor
9%
Thapsigargin
8%
Docetaxel
8%
Androgen Deprivation Therapy
8%
Abiraterone
8%
Recurrent Prostate Cancer
8%
Androgens
7%
Phase II Trial
7%
Androgen Receptor Splice Variant 7
7%
Placebo
7%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
7%
Advanced Prostate Cancer
6%
Prostate Cancer Cells
5%
Oligometastatic Prostate Cancer
5%
Testosterone
5%
Prodrug
5%
Prostate
5%
Mesenchymal Stem Cells
5%
Androgen Receptor Antagonist
5%
Medicine and Dentistry
Prostate Cancer
66%
Castration Resistant Prostate Cancer
21%
Androgen Receptor
20%
Androgen Therapy
15%
Prostate Specific Antigen
15%
Androgen
11%
Enzalutamide
10%
Radiation Therapy
8%
Neoplasm
8%
Abiraterone
7%
Cancer Cell
6%
Placebo
6%
Prostatectomy
6%
Targeted Therapy
6%
Disease
6%
Cancer Therapy
5%
Programmed Cell Death
5%
Mesenchymal Stem Cell
5%
Metastatic Carcinoma
5%
Malignant Neoplasm
5%
Prostate Specific Membrane Antigen
5%